Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

about

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.What are the prospects of apolipoprotein profiling for cardiovascular disease?

P2860

Q42357375-839C0297-766A-4F01-A8E2-9CE9F684CD03 Q48155948-E2730F73-9668-4070-922B-28709729B5B1

P2860

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

Item

http://www.wikidata.org/entity/Q40214593

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Apolipoprotein C-III Levels an ...... Prospective Population Study.

@en

type

Item

label

Apolipoprotein C-III Levels an ...... Prospective Population Study.

@en

prefLabel

Apolipoprotein C-III Levels an ...... Prospective Population Study.

@en

P1476

Apolipoprotein C-III Levels an ...... Prospective Population Study.

@en

P2093

Aeilko H Zwinderman

http://www.w3.org/2001/XMLSchema#string

Erik S G Stroes

http://www.w3.org/2001/XMLSchema#string

G Kees Hovingh

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Julian C van Capelleveen

http://www.w3.org/2001/XMLSchema#string

S Matthijs Boekholdt

http://www.w3.org/2001/XMLSchema#string

Sophie J Bernelot Moens

http://www.w3.org/2001/XMLSchema#string

Xiaohong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway

Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis

Common variants associated with plasma triglycerides and risk for coronary artery disease

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

P304

1206-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.117.309007

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28473441

http://www.w3.org/2001/XMLSchema#string

P932

5484077

http://www.w3.org/2001/XMLSchema#string

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

about

P2860

P2860

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932